Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cangrelor tetrasodium is a reversible and selective antagonist of platelet P2Y12, with prompt and potent antiplatelet effects.
説明 | Cangrelor tetrasodium is a reversible and selective antagonist of platelet P2Y12, with prompt and potent antiplatelet effects. |
In vitro | cangrelor, a non-sepesific GPR17 antagonist, alleviates pulmonary fibrosis partly by inhibiting macrophage inflammation in mice.Cangrelor is also a well-known anti-platelet agent. cangrelor (10 mg/kg) not only significantly decreased BLM-induced release of inflammatory cytokines (PF4, CD40 L and MPO), but also decreased the increment of platelets, neutrophils and platelet-neutrophil aggregates in the fibrotic lung and in the peripheral blood of BLM-treated mice. In addition, cangrelor decreased the number of CD40 and MPO double positive neutrophils and the expression level of CD40 in BLM-treated mouse lungs[1]. |
分子量 | 864.29 |
分子式 | C17H21Cl2F3N5Na4O12P3S2 |
CAS No. | 163706-36-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 8.65 mg/mL (10 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
cangrelor tetrasodium 163706-36-3 Endocrinology/Hormones GPCR/G Protein Neuroscience GPR P2Y Receptor aggregation fibrosis pulmonary platelet Inhibitor inflammation intravenous cangrelor antiplatelet inhibit inhibitor